Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-TCR-T Cells for EBV-HLH or EBV Infection
NCT06135922Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBV TCR-T cells in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and Epstein-Barr virus infection, sponsored by Chinese PLA General Hospital. Primary endpoint: Adverse events at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
EBV TCR-T cells
03
Conditions
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT06135922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135922.